Literature DB >> 24590645

Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer.

Daniel J Zabransky1, Ben Ho Park.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24590645     DOI： 10.1200/JCO.2013.53.5070

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

Review 2.  Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.

Authors:  Frederik Holst
Journal:  World J Clin Oncol       Date:  2016-04-10

Review 3.  Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.

Authors:  Lydia Wt Cheung; Gordon B Mills
Journal:  Pharmacogenomics       Date:  2016-01-25       Impact factor: 2.533

4.  Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Authors:  Frederik Holst; Erling A Hoivik; William J Gibson; Amaro Taylor-Weiner; Steven E Schumacher; Yan W Asmann; Patrick Grossmann; Jone Trovik; Brian M Necela; E Aubrey Thompson; Matthew Meyerson; Rameen Beroukhim; Helga B Salvesen; Andrew D Cherniack
Journal:  Sci Rep       Date:  2016-05-10       Impact factor: 4.379

Review 5.  RET in breast cancer: pathogenic implications and mechanisms of drug resistance.

Authors:  Cristiana Lo Nigro; Marta Rusmini; Isabella Ceccherini
Journal:  Cancer Drug Resist       Date:  2019-12-19

6.  Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.

Authors:  Harald Hessel; Manuela Poignée-Heger; Sabine Lohmann; Bianca Hirscher; Andrea Herold; Gerald Assmann; Jan Budczies; Karl Sotlar; Thomas Kirchner
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.